The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).
Jacek K. Pinski
No relevant relationships to disclose
Andrew V. Schally
Research Funding - Aeterna Zentaris
Denice D Tsao-Wei
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose
Susan G. Groshen
No relevant relationships to disclose
Shigang Xiong
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose
Yu-Chong Tai
No relevant relationships to disclose
Juergen Engel
Employment or Leadership Position - Aeterna Zentaris
Stock Ownership - Aeterna Zentaris
Stephen V. Liu
No relevant relationships to disclose